Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05689333 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery
A NA study of Vitrectomy, sponsored by VISTA Ophthalmics.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT05689333: Completed NA study of Vitrectomy, sponsored by VISTA Ophthalmics.
NCT05689333 is a NA study of Vitrectomy that has completed, run by VISTA Ophthalmics. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05689333, a NA study of Vitrectomy, has completed, sponsored by VISTA Ophthalmics.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, single-arm, non-comparative, open-label, monocular, post approval study to assess safety and device performance of the Vista Vitrectomy Probe during vitrectomy surgery.
Primary Outcome
Calculate the incidence of post-operative rates of retinal tears
Conditions Studied
Interventions
- DEVICE Vista Vitrectomy Probe
Study Locations (4)
California
- CBCC Global Research Site:003 - Los Angeles
Florida
- CBCC Global Research Site:002 - Bradenton
Pennsylvania
- CBCC Global Research Site:001 - Bala-Cynwyd
Texas
- CBCC Global Research Site:004 - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2024-05-07 |
| Phase | NA |
What the finished NCT05689333 record still lists
NCT05689333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Vitrectomy appearing as the primary indexed condition, and to 1 intervention - of which Vista Vitrectomy Probe is the first listed.
NCT05689333 reports a single indexed study location in California, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05689333 about?
NCT05689333 is a clinical study titled "A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery". This is a prospective, single-arm, non-comparative, open-label, monocular, post approval study to assess safety and device performance of the Vista Vitrectomy Probe during vitrectomy surgery.
What is the current status of trial NCT05689333?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2022-12-09. Estimated completion is 2024-05-07.
What conditions does trial NCT05689333 study?
This clinical trial studies the following conditions: Vitrectomy.
What interventions are being tested in trial NCT05689333?
The interventions under investigation include: Vista Vitrectomy Probe (DEVICE).
Who is sponsoring clinical trial NCT05689333?
This trial is sponsored by VISTA Ophthalmics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05689333 being conducted?
This trial has 4 study locations across California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitrectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05689333's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI